INHANCE Consortium

摘要 每年有近60万例头颈癌（HNC）病例被诊断出来，32.5万例死亡， HNC在世界上HNC是一组发生在口腔、口咽、下咽和 喉癌他们一起研究，因为他们共同的风险因素，烟草和酒精，但他们每个人都有 独特的流行病学和临床特征。例如，人乳头瘤病毒（HPV）感染是一个很大的风险， 这是口咽癌的一个特异性因素，并导致其发病率不断上升。国际 头颈癌流行病学（INHANCE; http://www.inhance.utah.edu）联盟，成立于 2004年，是一个非常富有成效的财团，在HNC研究方面有着出色的合作记录。虽然 在HNC研究方面取得了很大进展，以确定生活方式风险因素和基因，挑战 包括与患者更直接相关的子站点分组和研究结果。我们的会议将 汇集世界各地的HNC流行病学专家，目标如下：1）设立一个负责人， 颈部癌症子网站共识小组，2）讨论基于人群的头部 和颈部癌症患者队列提供患者和临床医生需要的信息，3）头部和 低收入和中等收入国家的颈癌研究（LMIC）。HNC子站点分组有 几十年来，这种分类方法不断发展，但并不是该领域的所有研究人员都采用了这种新的分类方法。各种癌 迄今为止的登记报告包括鼻咽癌和唾液腺癌， 咽癌将这些不同的疾病组合在一起是不合适的，并且会造成癌症的混淆 趋势和风险因素。共识小组将起草一份文件，为未来的子站点分组提出建议。 问题研究此外，尽管INHANCE联盟传统上专注于识别风险因素， 为HNC患者提供基本信息的研究是流行病学家可以做出贡献的领域 这与基于人口的研究密切相关。目前的NCCN生存指南指出“确切的 癌症及其治疗的各种影响的患病率很难量化，因为很少有研究 以纵向方式解决这些问题。总的来说，癌症幸存者中晚期效应的患病率 据信随着时间的推移而增加，可能是因为抗癌干预变得更加复杂 和强烈的..."我们将讨论HNC未来可能的研究、合作和优先假设 患者队列，重点关注癌症幸存者的晚期效应。HNC流行病学家潜力巨大 为HNC幸存者的NCCN等临床指南做出贡献，并可能为治疗决策做出贡献 在精心设计的流行病学研究中适当描述了治疗的迟发效应。 最后，大多数头颈癌病例是在LMIC中诊断的，但大多数研究都是在LMIC中诊断的。 在高收入国家进行。我们将讨论头部和颈部的高优先级研究领域 在低收入国家中的癌症，以最大限度地减少这种疾病的发病率和死亡率的影响。

ABSTRACT Each year almost 600,000 head and neck cancers (HNC) cases are diagnosed and 325,000 deaths occur due to HNC in the world. HNC are a group of malignant cancers in the oral cavity, oropharynx, hypopharynx and larynx. They are studied together due to their shared risk factors of tobacco and alcohol, but they each have distinct epidemiologic and clinical features. For instance, human papillomavirus (HPV) infection is a strong risk factor specifically for oropharyngeal cancers and is contributing to it’s increasing incidence. The International Head and Neck Cancer Epidemiology (INHANCE; http://www.inhance.utah.edu) Consortium, established in 2004, is a very productive consortium with an excellent record of collaboration on HNC research. Although great advances have been made in HNC research to identify lifestyle risk factors and genes, challenges include subsite groupings and research results that are more directly relevant to patients. Our meeting will bring together the world’s experts on HNC epidemiology with the following aims: 1) to establish a Head and Neck Cancer Subsite Grouping Consensus Panel, 2) to discuss the potential of population-based head and neck cancer patient cohorts on providing information that patients and clinicians need and 3) head and neck cancer research in low and middle income countries (LMIC). The HNC subsite groupings have evolved over the decades, but not all researchers in the field have adopted the new groupings. Various cancer registry reports to this day include nasopharyngeal cancers and salivary gland cancers as ‘oral cavity and pharynx’ cancers. Combining such distinct diseases together is inappropriate and creates confusion for cancer trends and risk factors. The Consensus Panel will draft a paper to propose the subsite groupings for future studies. Additionally, although the INHANCE consortium has traditionally focused on identifying risk factors, studies that provide basic information for HNC patients is an area that epidemiologists can contribute to significantly with robust population-based studies. The current NCCN survivorship guideline states “The exact prevalence of various effects of cancer and its treatment are hard to quantify, because few studies have addressed these issues in a longitudinal fashion. In general, the prevalence of late effects in cancer survivors in believed to have increased over time, likely because anticancer interventions have become more complex and intense …”. We will discuss potential future studies, collaborations, and priority hypotheses for HNC patient cohorts with a focus on late effects among cancer survivors. HNC epidemiologists have great potential to contribute to clinical guidelines such as the NCCN for HNC survivors and possibly for treatment decisions when late effects due to treatments are characterized appropriately in well-designed epidemiologic studies. Finally, the majority of head and neck cancer cases are diagnosed in LMICs, but the majority of research is conducted in high income countries. We will discuss the high priority areas of research for head and neck cancer in LMIC for maximal impact to reduce the morbidity and mortality of this disease in LMICs.